Saturday, December 1, 2018

Global trial shows CAR T therapy can lead to durable remissions in non-Hodgkin's lymphoma

In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

from Top Health News -- ScienceDaily https://ift.tt/2Q7y3t5
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

JWST spots a strange red dot so extreme scientists can’t explain it

The discovery of strange, ultra-red objects—especially the extreme case known as The Cliff—has pushed astronomers to propose an entirely new...